Your browser doesn't support javascript.
loading
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Flaifel, Abdallah; Xie, Wanling; Braun, David A; Ficial, Miriam; Bakouny, Ziad; Nassar, Amin H; Jennings, Rebecca B; Escudier, Bernard; George, Daniel J; Motzer, Robert J; Morris, Michael J; Powles, Thomas; Wang, Evelyn; Huang, Ying; Freeman, Gordon J; Choueiri, Toni K; Signoretti, Sabina.
Afiliação
  • Flaifel A; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Xie W; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Braun DA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Ficial M; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Bakouny Z; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Nassar AH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Jennings RB; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Escudier B; Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
  • George DJ; Department of Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
  • Motzer RJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York.
  • Morris MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York.
  • Powles T; Department of Experimental Cancer Medicine, Barts Cancer Institute, London, United Kingdom.
  • Wang E; Exelixis Inc., South San Francisco, California.
  • Huang Y; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Freeman GJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. ssignoretti@partners.org Toni_Choueiri@dfci.harvard.edu.
  • Signoretti S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. ssignoretti@partners.org Toni_Choueiri@dfci.harvard.edu.
Clin Cancer Res ; 25(20): 6080-6088, 2019 10 15.
Article em En | MEDLINE | ID: mdl-31371341
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Inibidores de Proteínas Quinases / Antígeno B7-H1 / Neoplasias Renais Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Biomarcadores Tumorais / Inibidores de Proteínas Quinases / Antígeno B7-H1 / Neoplasias Renais Idioma: En Ano de publicação: 2019 Tipo de documento: Article